LH

Labcorp Holdings Inc.

LHHealthcareNASDAQ

Diagnostics & Research

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$13.95B
+7.2% YoY
Net Income
$876.5M
+17.5% YoY
EBITDA
$2.01B
+11.1% YoY
Free Cash Flow
$892.0M

Scan Results

Daily timeframe
DateIndicatorDetails
Sep 1 MACD Negative CrossoverHistogram -0.7652, negative momentum
Aug 31CONFIRMED MACD Negative CrossoverHistogram -0.3295, negative momentum
RSI OverboughtRSI 70.0, above 70, stock may be overbought
About Labcorp Holdings Inc.

Labcorp Holdings Inc. provides laboratory services. The company carries a $26.51B market cap, placing it firmly in the large-cap category. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments.

Where LH stands vs its 150-day and 200-day moving averages

As of the September 1, 2026 close, LH finished 19.80% above its 150-day moving average ($277.68) and 21.88% above its 200-day moving average ($272.95). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is LH overbought or oversold?

At the September 1, 2026 close, LH's RSI(14) was 64.6, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$26.51B
P/E (TTM)27.04
Fwd P/E16.49
EPS$12.09
Beta0.85
52W Change+17.5%
Dividend Yield0.88%
ROE11.7%
Analysis

On the balance sheet, LH has $141.8M in cash with $6.82B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $892.0M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 11.7% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.5% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $11.86B to $13.95B.

The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Labcorp Holdings Inc.'s trajectory.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms